Is there a generic version of Revumenib produced in India?

There is no generic version of Revumenib produced in India. Revimenib is a new oral small molecule inhibitor targeting KMT2A (MLL) rearrangement-related mutations. It is mainly used to treat KMT2A rearrangement or < span>NPM1Mutation relapse/Patients with refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The drug was developed by Syndax Pharmaceuticals of the United States. Due to its novel mechanism of action and preliminary clinical efficacy, it is still in the approval or early marketing stage of international drug regulatory agencies and has not yet been approved in China.

There are two main reasons why there are no generic versions of Revimenib. First of all, it is a newly approved innovative drug that is still in its early stages of global use and is still under patent protection. Countries such as India and other major generic drug countries are unable to legally produce and sell generic versions of it due to patent restrictions. Secondly, the targeting pathways involved in Revimenib are relatively complex, and the synthesis process and activity control requirements are extremely high. Even after the patent is opened, the development of its generic process will require a long period of time and technology accumulation.

In addition, India has had technical and policy advantages in copying certain anti-cancer targeted drugs in the past, but it usually starts the generic process only after the original drug has been on the market for many years and the patent is approaching or has expired. Considering that Revimenib is still in the early stages of its launch and its market size is still being established, even if its Indian generic version is launched in the future, it will take time to advance. Therefore, if patients need to use the drug in the short term, they can only obtain it through overseas original research channels.

In short, Revimenib is currently only available in the form of the original drug globally, and there is no generic version in India or other countries to replace it. For patients in need of medicines, it is recommended to apply for imported original medicines through formal cross-border medical service platforms or medical institutions, and always use them under the guidance of doctors. In the future, if the drug is approved in China and completes its patent period, whether there will be a generic version still depends on policy, market and technological progress.

Reference materials:https://www.drugs.com/